Notes / Company

Colinz Laboratories Ltd.

COLINZ BSE 531210 ISIN INE923C01011 Pharmaceuticals

Fundamentals

Market cap: ₹19.03 cr
P/E: 37.10×
ROE: 5.24%
Debt / equity: 0.07
52-week range: 36.11 — 87.91

Research on Tijori Finance

Company snapshot

Colinz Laboratories Ltd.

Pharmaceuticals

₹17 cr

P/E 32.66×

Latest quarter · Mar 2026

Sales₹2 cr

Net profit₹0 cr

Op. margin+5.2%

EPS₹0.67

Strength & growth

Debt / equity0.07×

Current ratio4.17×

Sales CAGR−2.9%

EPS CAGR+23.0%

The timeline — 1 note on Colinz Laboratories Ltd.

June 2026

18 Jun 26 · 5:14 PM IST Alert

Alert · M&A · Micro cap

Dugar family launches open offer for 26% of Colinz at ₹54/share

A mandatory open offer follows a share purchase agreement for a 34.56% stake, handing control of the nano-cap pharma company to the Dugar family for a combined ₹7.89 crore, over half its market cap.

Verify on exchange BSE filings for COLINZ NSE filings for COLINZ Tijori Finance company page